EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Present and future of resistance in Pseudomonas aeruginosa: implications for treatment

M Pina-Sánchez, M Rua, J L Del Pozo

Revista Española de Quimioterapia · 2023

DOI: 10.37201/req/s01.13.2023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Revista Española de Quimioterapia, 2023. Verfasst von M Pina-Sánchez und 2 weiteren Autor:innen. Beteiligte Einrichtung: José Luis Del Pozo, Department of Clinical Microbiology, Clínica Universidad de Navarra, Pamplona, Spain. jdelpozo@unav.es. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudomonas aeruginosa is a pathogen that has a high propensity to develop antibiotic resistance, and the emergence of multidrug-resistant strains is a major concern for global health. The mortality rate associated with infections caused by this microorganism is significant, especially those caused by multidrug-resistant strains. The antibiotics used to treat these infections include quinolones, aminoglycosides, colistin, and β-lactams. However, novel combinations of β-lactams-β-lactamase inhibitors and cefiderocol offer advantages over other members of their family due to their better activity against certain resistance mechanisms. Selecting the appropriate empiric antibiotic treatment requires consideration of the patient’s clinical entity, comorbidities, and risk factors for multidrug-resistant pathogen infections, and local epidemiological data. Optimizing antibiotic pharmacokinetics, controlling the source of infection, and appropriate collection of samples are crucial for successful treatment. In the future, the development of alternative treatments and strategies, such as antimicrobial peptides, new antibiotics, phage therapy, vaccines, and colonization control, holds great promise for the management of P. aeruginosa infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas InfectionsHumansAnti-Bacterial AgentsColistinbeta-Lactamsbeta-Lactamase InhibitorsDrug Resistance, Multiple, BacterialMicrobial Sensitivity Tests

Substanzen

Anti-Bacterial AgentsColistinbeta-Lactamsbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • José Luis Del Pozo, Department of Clinical Microbiology, Clínica Universidad de Navarra, Pamplona, Spain. jdelpozo@unav.es.

Zitieren

APA

Pina-Sánchez, M., Rua, M., & Del Pozo, J. L. (2023). Present and future of resistance in Pseudomonas aeruginosa: implications for treatment. Revista Española de Quimioterapia. https://doi.org/10.37201/req/s01.13.2023

Vancouver

Pina-Sánchez M, Rua M, Del Pozo JL. Present and future of resistance in Pseudomonas aeruginosa: implications for treatment. Revista Española de Quimioterapia. 2023. doi:10.37201/req/s01.13.2023

BibTeX
@article{PinaSnchez2023,
  author = {Pina-Sánchez, M and Rua, M and Del Pozo, J L},
  title = {Present and future of resistance in Pseudomonas aeruginosa: implications for treatment},
  journal = {Revista Española de Quimioterapia},
  year = {2023},
  doi = {10.37201/req/s01.13.2023}
}
Kostenlos starten →